Evaluation and comparison of physicochemical properties, cytotoxicity and the ability of miRNA loading of different  cationic liposomes for gene therapy application

Nikoonahad Lotfabadi, Narges; Mohseni Kouchesfehani, Homa; Sheikhha, Mohammad Hasan; Kalantar, Seyed Mehdi

Volume 25, Issue 6 (Aug 2017) JSSU 2017, 25(6): 444-456 | Back to browse issues page

Mendeley

Zotero

RefWorks

Nikoonahad Lotfabadi N, Mohseni Kouchesfehani H, Sheikhha M H, Kalantar S M. Evaluation and comparison of physicochemical properties, cytotoxicity and the ability of miRNA loading of different cationic liposomes for gene therapy application. JSSU 2017; 25 (6) :444-456
URL: http://jssu.ssu.ac.ir/article-1-4299-en.html

Evaluation and comparison of physicochemical properties, cytotoxicity and the ability of miRNA loading of different cationic liposomes for gene therapy application

Narges Nikoonahad Lotfabadi

, Homa Mohseni Kouchesfehani ^*

, Mohammad Hasan Sheikhha

, Seyed Mehdi Kalantar

Abstract: (4895 Views)

Introduction: In the present study, various formulations of cationic liposomes were designed and prepared using different cationic lipids. It was performed to assess the physicochemical properties, miRNA loading ability and cellular toxicity rates of liposomes in order to use in gene therapy.
Methods: Different cationic liposome formulations (F1-F4) containing various cationic lipids, DOTAP, DOTMA, DOAB and DDAB with DPPC, cholesterol and phospholipid DSPE-mPEG were synthesized. Prepared nanoparticles were evaluated in term of particle size, polydisparity index, surface charge and cytotoxicity for 48 and 72 h in two cell lines. By using gel electrophoresis, the ability of synthesized cationic liposomes to entrap miRNA was also compared.
Results: All formulations were mono-dispersed. The particle size in F1, which contained DOTAP was lower than others (F2-F4) and its surface charge was more than them. Cationic liposomes based on DOTAP had no significant cytotoxicity as compared to other formulations. Also, F1 formulation was more capable to entrap miRNA than other formulas.
Conclusion: DOTAP-based cationic liposomes can be used efficiently in the gene therapy process, especially for the transfer of miRNA as a new therapeutic agent in cancer therapy

Keywords: miRNA, liposome, cytotoxicity, gene therapy

Full-Text [PDF 840 kb] (1575 Downloads)

Type of Study: Original article | Subject: Biology
Received: 2017/08/21 | Accepted: 2017/09/16 | Published: 2017/10/25

References

1. Mitra AK, Agrahari V, Mandal A, Cholkar K, Natarajan C, Shah S, et al. Novel delivery approaches for cancer therapeutics. J Control Release 2015; 219: 248–68.

2. Sun N, Liu Z, Huang W, Tian A, Hu S. The research of nanoparticles as gene vector for tumor gene therapy. Crit Rev Oncol Hematol 2014; 89(3): 352–7.

3. Sperber GH, Sperber SM. Thompson and Thompson Genetics in Medicine. Cleft Palate-Craniofacial J 2008; 45(1): 106.

4. Li N, Zhao L, Qi L, Li Z, Luan Y. Polymer assembly: promising carriers as co-delivery systems for cancer therapy. Prog Polym Sci 2015; 58: 1–26.

5. del Burgo LS, Pedraz JL, Orive G. Advanced nanovehicles for cancer management. Drug Discov Today 2014; 19(10): 1659–70.

6. Jayakumar R, Chennazhi KP, Muzzarelli RAA, Tamura H, Nair SV, Selvamurugan N. Chitosan conjugated DNA nanoparticles in gene therapy. Carbohydr Polym 2010; 79(1): 1–8.

7. Husain SR, Han J, Au P, Shannon K, Puri RK. Gene therapy for cancer: regulatory considerations for approval. Cancer Gene Ther 2015; 22(12): 554-63.

8. Shim G, Kim M-G, Park JY, Oh Y-K. Application of cationic liposomes for delivery of nucleic acids. Asian J Pharm Sci 2013; 8(2): 72–80.

9. Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine 2014; 9: 467-83.

10. Caruso F, Hyeon T, Rotello V. Nanomedicine themed issue. Chem Soc Rev 2012; 41(7): 2537-2538.

11. Hull LC, Farrell D, Grodzinski P. Highlights of recent developments and trends in cancer nanotechnology research—View from NCI Alliance for nanotechnology in cancer. Biotechnol Adv. 2014; 32(4): 666–78.

12. Yoshino K, Taguchi K, Mochizuki M, Nozawa S, Kasukawa H, Kono K. Novel analytical method to evaluate the surface condition of polyethylene glycol-modified liposomes. Colloids Surfaces A Physicochem Eng Asp 2012; 397: 73–9.

13. Sabnani MK, Rajan R, Rowland B, Mavinkurve V, Wood LM, Gabizon AA, et al. Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses. Nanomedicine Nanotechnology, Biol Med 2015; 11(2): 259–62.

14. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012; 33(29): 7138–50.

15. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2(12): 751–60.

16. Chen Y, Gao D-Y, Huang L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv Drug Deliv Rev 2015; 81: 128–41.

17. Yang J, Liu H, Zhang X. Design, preparation and application of nucleic acid delivery carriers. Biotechnol Adv 2013; 32(4): 804–17.

18. Bose J, Arai Y, Chan Ahn J, Park H, Lee S-H. Influence of cationic lipid concentration on properties of lipid–polymer hybrid nanospheres for gene delivery. Int J Nanomedicine [Internet] 2015; 10: 5367–82.

19. Mady MM. Cationic liposomes as gene delivery system. African J Pharm Pharmacol 2011; 5(17): 2007–12

20. Haghiralsadat F, Amoabediny G, Helder MN, Naderinezhad S, Sheikhha MH, Forouzanfar T, Zandieh-doulabi B. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery. Artificial Cells, Nanomedicine, and Biotechnology 2017; 4: 1-9.

21. WHO. Cancer [Internet]. World Health Organization. 2017. Available from: http://www.who.int/ cancer/en/.

22. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res 2006; 4(3): 218–27.

23. Amer MH. Gene therapy for cancer: present status and future perspective. Mol Cell Ther 2014; 2: 27.

24. Bakhshandeh B, Soleimani M, Hafizi M, Ghaemi N. A comparative study on nonviral genetic modifications in cord blood and bone marrow mesenchymal stem cells. Cytotechnology 2012; 64(5): 523–40.

25. Cui S, Wang B, Zhao Y, Chen H, Ding H, Zhi D, et al. Transmembrane routes of cationic liposome-mediated gene delivery using human throat epidermis cancer cells. Biotechnol Lett. 2014; 36(1): 1–7.

26. Samadikhah HR, Nikkhah M, Hosseinkhani S. Enhancement of cell internalization and photostability of red and green emitter quantum dots upon entrapment in novel cationic nanoliposomes. Luminescence 2017; 32(4): 517–28.

27. Campbell RB, Balasubramanian S V., Straubinger RM. Phospholipid-cationic lipid interactions: Influences on membrane and vesicle properties. Biochim Biophys Acta-Biomembr 2001; 1512(1): 27–39.

28. Wang X, Yu B, Ren W, Mo X, Zhou C, He H, et al. Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. J Control release 2013; 172(3): 690–8.

29. Hattori Y, Nakamura A, Arai S, Kawano K, Maitani Y, Yonemochi E. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes. J Liposome Res [Internet]. Informa Healthcare USA, Inc 2015; 25(4): 279–86.

30. Al-Husaini K. Therapeutic Potential of CPP (NP1) Mediated siRNA Delivery: Evidence in 3D Spheroids of Colon Cancer Cells (HCT 116) (Master's thesis, University of Waterloo).

31. Ashizawa AT, Cortes J. Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01. Expert Opin Drug Deliv [Internet. 2015; (January 2013):1–14.

32. Khatri N, Baradia D, Vhora I, Rathi M, Misra A. Development and Characterization of siRNA Lipoplexes: Effect of Different Lipids, In Vitro Evaluation in Cancerous Cell Lines and In Vivo Toxicity Study. Aaps Pharmscitech 2014; 15(6): 1630–43.

33. Balazs DA, Godbey WT. Liposomes for Use in Gene Delivery. J Drug Deliv [Internet] 2011; 2011: 1–12.

34. Samadikhah HR, Majidi A, Nikkhah M, Hosseinkhani S. Preparation, characterization, and efficient transfection of cationic liposomes and nanomagnetic cationic liposomes. Int J Nanomedicine 2011; 6: 2275–83.

35. Kim BK, Hwang GB, Seu YB, Choi JS, Jin KS, Doh KO. DOTAP/DOPE ratio and cell type determine transfection efficiency with DOTAP-liposomes. Biochim Biophys Acta - Biomembr [Internet]. Elsevier B.V 2015; 1848(10): 1996–2001.

36. Ren T, Song YK, Zhang G, Liu D. Structural basis of DOTMA for its high intravenous transfection activity in mouse. Gene Ther 2000; 7(9): 764–8.

37. Antimisiaris S, Mourtas S, Papadia K. Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential. International J Pharmaceutics. Elsevier B.V 2017; 525(2): 293-312.

38. Hattori Y, Yoshiike Y, Honda M, Ohno H, Onishi H. Evaluation of Small Interfering RNA Delivery into Cells by Reverse Transfection in Suspension with Cationic Liposomes. Pharmacol Pharm 2017; 8(5): 129–39.

39. Mel’nikov SM, Lindman B. Solubilization of DNA-cationic lipid complexes in hydrophobic solvents. A single-molecule visualization by fluorescence microscopy. Langmuir 1999; 15(6): 1923–8.

40. Mizuarai S, Ono K, You J, Kamihira M, Iijima S. Protamine-modified DDAB lipid vesicles promote gene transfer in the presence of serum. J Biochem 2001; 129(1): 125–32.

41. Peng Z, Fang E, Wang C, Lu X, Wang G, Tong Q. Construction of Novel Thermosensitive Magnetic Cationic Liposomes as a Drug and Gene Co-Delivery System. J Nanosci Nanotechnol 2015; 15(5): 3823–33.

42. Spring BQ, Sears RB, Zheng LZ, Mai Z, Watanabe R, Sherwood ME, et al. A photoactivable multi-inhibitor nanoliposome for tumout control and simultaneous inhibition of treatment escape pathways. Nat Nanotechnol [Internet]. Nature Publishing Group 2016; 11(4): 378–89.

43. Ziraksaz Z, Nomani A, Soleimani M, Bakhshandeh B, Arefian E, Haririan I, et al. Evaluation of cationic dendrimer and lipid as transfection reagents of short RNAs for stem cell modification. Int J Pharm [Internet]. Elsevier B.V. 2013; 448(1): 231–8.